Browse News
Filter News
Found 45 articles
-
AstraZeneca Full year and Q4 2023 Financial Results
2/8/2024
Strong growth and pipeline momentum with three new medicines approved since the third quarter
-
NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
5/16/2023
NanoViricides, Inc., reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission on Monday, May 15, 2023.
-
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
1/23/2023
BiondVax Pharmaceuticals Ltd. today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug.
-
FDA Roundup: January 6, 2023
1/6/2023
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
-
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Curia Global, Inc.
12/12/2022
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has obtained an exclusive license from Curia Global, Inc., a leading contract research, development and manufacturing organization, for the development of three humanized murine monoclonal antibodies (mAbs) for the treatment or prophylaxis of SARS-CoV-2 infection. SARS-CoV-2 is the cause of COVID-19.
-
Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress
11/30/2022
Tonix Pharmaceuticals Holding Corp. today announced data from its fully human anti-SARS-CoV-2 monoclonal antibody platform in an oral presentation delivered by Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, at the World Antiviral Congress 2022 in San Diego, Calif.
-
AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022
11/10/2022
TIME named AstraZeneca’s EVUSHELD on their 2022 list of Best Inventions.
-
EVUSHELD RECEIVES HEALTH CANADA APPROVAL FOR TREATMENT OF COVID-19
10/18/2022
AstraZeneca's Evusheld™ (tixagevimab and cilgavimab), a long-acting antibody combination has received a Notice of Compliance from Health Canada for the treatment of mild to moderate COVID-19 in adults and adolescents (≥12 years of age weighing at least 40 kg).
-
FDA Roundup: October 4, 2022
10/4/2022
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
-
In an interview with Reuters, AstraZeneca CEO Pascal Soriot said Tuesday that he isn't sure if the company will continue developing vaccines. He also hinted at potential M&A action.
-
Innate Pharma announced that a planned futility interim analysis of the INTERLINK-1 Phase III trial sponsored by AstraZeneca failed to hit a pre-defined threshold for efficacy.
-
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
7/28/2022
Todos Medical, Ltd. today announced that its CLIA/CAP certified clinical laboratory Provista Diagnostics has entered into an agreement with Amerimmune Diagnostics, a CLIA/CAP certified laboratory with expertise in immune diagnostics and a leader in the field of clinical immunology and immune assessment of acute and long-COVID.
-
Researchers evaluate just how well therapeutic antibodies and antivirals work against Omicron, Vaxart's oral vaccine shows early promise and hypertension doubles the risk of hospitalization.
-
While a handful of companies have dominated the COVID-19 vaccine market in the U.S. and Europe, a number of biotechs are continuing to develop vaccines to use as booster shots.
-
Results of the Phase III trial showed that Evusheld protected against progression to severe COVID-19 or death in the early outpatient treatment of mild-to-moderate COVID-19.
-
Evusheld long-acting antibody combination retains neutralising activity against Omicron variants BA.4 and BA.5, according to new study from University of Oxford
5/25/2022
Evusheld long-acting antibody combination retains neutralising activity against Omicron variants BA.4 and BA.5, according to new study from University of Oxford
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
As Omicron dominates the COVID-19 landscape, scientists are urging the FDA to reconsider how the agency defines immune responses.
-
Clinical results announced this week could expand COVID-19 prevention options for the immunocompromised and vaccine ineligible, as well as those that have already contracted COVID.
-
EVUSHELD™ significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
4/20/2022
Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s EVUSHELD™ (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and by 83% in the six-month follow-up analysis, compared to placebo.